Fabry Disease Podocytes Reveal Ferroptosis as a Potential Regulator of Cell Pathology
These findings underscore the heterogeneity of FD and, for the first time, implicate ferroptosis as a potential common pathway driving its pathology.
Authors
- Xiangju Wang (ORCID: https://orcid.org/0000-0002-9787-6951)
- Sheetal Saini (ORCID: https://orcid.org/0000-0001-6229-4487)
- Andrea F. Wise (ORCID: https://orcid.org/0000-0002-9387-4465)
- Maria Fuller (ORCID: https://orcid.org/0000-0001-9092-8942)
- Kathy Nicholls (ORCID: https://orcid.org/0000-0002-1297-8722)
- Shoni Bruell
- Joel R. Steele (ORCID: https://orcid.org/0000-0002-3070-9761)
- Helen Healy (ORCID: https://orcid.org/0000-0003-4342-5300)
- Tejasvini Bhuvan
- Andrew J. Kassianos (ORCID: https://orcid.org/0000-0002-0994-3588)
- Han-Chung Lee (ORCID: https://orcid.org/0000-0002-9858-757X)
- Elizabeth L. Qian (ORCID: https://orcid.org/0009-0008-7323-8112)
- Sharon D. Ricardo (ORCID: https://orcid.org/0000-0003-1724-3669)
- David Elliot
- Igaa Ari Krisnadevi
Institutions
- The Royal Melbourne Hospital (AU)
- Royal Children's Hospital (AU)
- Royal Brisbane and Women's Hospital (AU)
- Discovery Institute (US)
- Australian Regenerative Medicine Institute (AU)
- Women's and Children's Hospital (AU)
- Monash University (AU)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2024-11-23
- DOI
- https://doi.org/10.1016/j.ekir.2024.11.024
- Citations
- 7
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 2.37
Funders
- Sanofi
- Takeda Pharmaceutical Company
- Shire Human Genetic Therapies
- Monash University
- Novo Nordisk
- Novo Nordisk Fonden
- Sanofi Genzyme